Mok CC, van der Kleij D, Wolbink GJ (2013) Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol 32:1429–1435Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti...
Marcelli, `Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective', Ann. Rheum. Dis., vol. 72, no. 2, pp. 165-178, Feb. 2013....
Biologic drugs have transformed the standard of care for many diseases. However, many biologics induce the formation of anti-drug antibodies (ADAs), which can compromise their safety and efficacy. Preclinical studies demonstrate that biodegradable nanoparticles-encapsulating rapamycin (ImmTOR), but not f...
antidrug antibodydrug clearanceinfliximabpharmacokineticsTreatment of patients with biologics such as infliximab may trigger development of antidrug antibodies, which are associated with faster drug clearance, reduced treatment efficacy, and increased risk of infusion-related reactions. The aim of this study...
Production of anti drug antibodies (ADA) in adalimumab treated RA patients is associated with reduced serum adalimumab levels and less clinical response. H... Pauline A. van Schouwenburg a b,Geertje M. Bartelds b,Margreet H. Hart a,... - 《Journal of Immunological Methods》 被引量: 224发...
Indeed, Anti-Drug Antibodies (ADAbs) formation, as a consequence of biologics immunogenicity, has been associated with treatment failure and adverse effects, such as hypersensitivity reactions6. ADAbs are observed in patients treated with Adalimumab at a rate of up to 8% of patients after 8 weeks...
An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of h... Anti-drug vaccines to treat substance abuse. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases...
Anti-drug antibodies Incidence of ADAs Subjects were divided into four TE-ADA analysis populations depending on their maximum TE-ADA titer reached during 60 weeks of treatment. Titer subgroups included TE-ADA negative, TE-ADA low (maximum titer < 1:160), TE-ADA moderate (maximum titer ≥ 1:...
Immunoassay Design using a Biotin‐Extraction Acid Dissociation (BEAD) Sample Pretreatment for the Detection of Anti‐Drug Antibodies in the Presence of High Concentrat... lenge. Traditionally, PEGylated com- pounds have been analyzed by first hydrolyzing the polymer and then extracting the small molec...
WuXi Biologics ("WuXi Bio") (2269.HK) and Toregem BioPharma today announced that they have signed a Memorandum of Understanding (MOU) to form a strategic partnership in the development of TRG035, a monoclonal antibody targeting USAG-1 for the treatment o